Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.36 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27695212 | 0.89 | DRD2 (0.40) | DRD2DRD3SLC6A4HTR2AHTR1A | |
| SCHEMBL5184704 | 0.89 | DRD2 (0.40) | DRD2DRD3SLC6A4HTR2AHTR1A | |
| SCHEMBL21815350 | 0.79 | HTR2A (0.41) | SLC6A4HTR2AHTR1ASLC6A2HTR2B | |
| SCHEMBL578547 | 0.79 | HTR2A (0.41) | SLC6A4HTR2AHTR1ASLC6A2HTR2B | |
| SCHEMBL1551829 | 0.79 | DRD2 (0.42) | DRD2DRD3SLC6A4HTR2AHTR1A | |
| SCHEMBL27828941 | 0.79 | DRD2 (0.42) | DRD2DRD3SLC6A4HTR2AHTR1A | |
| SCHEMBL1552182 | 0.77 | ADRA2C (0.51) | SLC6A4HTR2AHTR1ASLC6A2HTR2B | |
| SCHEMBL1551851 | 0.77 | ADRA2C (0.51) | SLC6A4HTR2AHTR1ASLC6A2HTR2B | |
| SCHEMBL1551849 | 0.77 | ADRA2C (0.51) | SLC6A4HTR2AHTR1ASLC6A2HTR2B | |
| SCHEMBL5200710 | 0.77 | CDK1 (0.44) | DRD2DRD3SLC6A4HTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025119216-A1 | BORONIC ACID β-LACTAMASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 珠海联邦制药股份有限公司 | 2025-06-12 | — | — | WO | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | DRD2 259/4885DRD3 398/4885SLC6A4 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.